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Adipocyte renewal from preadipocytes has been shown to occur
throughout life and to contribute to obesity, yet very little is
known about the molecular circuits that control preadipocyte
expansion. The soluble form of the preadipocyte factor (also
known as pref-1) delta-like 1 homolog (DLK1S) is known to in-
hibit adipogenic differentiation; however, the impact of DLK1
isoforms on preadipocyte proliferation remains to be determined.
We generated preadipocytes with different levels of DLK1 and
examined differentially affected gene pathways, which were
functionally tested in vitro and conﬁrmed in vivo. Here, we dem-
onstrate for the ﬁrst time that only membrane-bound DLK1
(DLK1M) exhibits a substantial repression effect on preadipocyte
proliferation. Thus, by independently manipulating DLK1 isoform
levels, we established that DLK1M inhibits G1-to-S-phase cell cycle
progression and thereby strongly inhibits preadipocyte proliferation
in vitro. Adult DLK1-null mice exhibit higher fat amounts than wild-
type controls, and our in vivo analysis demonstrates that this may be
explained by a marked increase in preadipocyte replication. To-
gether, these data imply a major dual inhibitory function of DLK1
on adipogenesis, which places DLK1 as a master regulator of pre-
adipocyte homeostasis, suggesting that DLK1manipulation may open
new avenues in obesity treatment. Diabetes 61:2814–2822, 2012
Obesity is a major risk factor for metabolic dis-orders such as type 2 diabetes and cardiovas-cular disease. Excessive dietary fat intake leadsto expansion of adipose tissue, which, at the
cellular level, is known to occur as a result of adipocyte
hypertrophy; most recently it also has been demonstrated
to be caused by an increase in the number of adipocytes
during both childhood and adulthood (1–3). The latter
certainly opens up new possibilities for developing novel
strategies to treat or prevent obesity; however, the mech-
anisms responsible for preadipocyte proliferation are in-
completely understood (4). Adipocytes originate from
preadipocytes, for example, fat progenitors located in
the stromal vascular fraction of adipose tissue. Little is
known so far about the biology of these preadipocytes, but
recent in vivo cell lineage tracing studies using peroxisome
proliferator-activated receptor g, a master regulator of adi-
pogenesis, have suggested that preadipocytes in white
adipose tissue are characterized by the expression of
delta-like 1 homolog (Dlk1), GATA3,Wisp2, Smo, and Gli3
(4). Dlk1, also known as preadipocyte factor 1 (Pref-1), is
a paternally expressed imprinted gene that encodes for
a membrane protein member of the NOTCH receptor and
ligand epidermal growth factor–like protein family (5,6).
Dlk1 has been linked to the inhibition of adipogenesis,
especially in studies using the preadipocyte cell line 3T3-
L1, where Dlk1 is highly expressed during proliferation but
downregulated upon adipogenic differentiation (7,8). Al-
ternative splicing generates various forms of membrane-
spanning DLK1 proteins that differ by in-frame deletions of
an extracellular juxtamembrane protease recognition site
(9). Thus, DLK1 isoforms lacking this region remain teth-
ered to the membrane, whereas variants encompassing the
protease recognition site can be processed to generate the
large, active soluble DLK1S isoform (10) that is released
into circulation (11) (Fig. 1A). Despite its well-known im-
plication in adipogenesis, Dlk1’s mechanism of action still
remains a large topic for discussion, and the interaction
partner(s) still remains to be determined deﬁnitively (6,12–
17). Thus, further insights into DLK1 signaling in pre-
adipocytes will be important, and may serve to further
unravel whether DLK1 itself or related interaction partners
could serve as novel candidate targets in obesity therapy.
DLK1M and soluble DLK1 isoforms both have been
shown to be involved in adipogenesis; however, their sig-
niﬁcance and actual roles in this process are still debated
(7,10,18), and little attention has been given to DLK1’s role
in preadipocyte proliferation. Interestingly, Dlk1-null mice
display considerably increased fat mass compared with
wild-type controls, but this was concluded previously,
reﬂecting adipocyte hypertrophy rather than hyperplasia
(19). Vice versa, reduced fat mass due to decreased cell
size has been reported for mice that overexpress DLK1S
(20). DLK1 thus has been shown to be a major inhibitor of
adipogenesis, and although questioned, this inhibitory
function has been ascribed solely to the large soluble form
of DLK1 interfering with adipocyte differentiation (10).
However, neither of these studies investigated the impact
of DLK1 on preadipocyte proliferation. This led us to test
the effect of DLK1 on preadipocyte proliferation in vitro
and in vivo and speciﬁcally whether differential roles exist
for DLK1M and soluble DLK1 isoforms.
RESEARCH DESIGN AND METHODS
Animals. Dlk12/2 and Dlk1+/+ C57BL/6 mice (21) were backcrossed to C57BL/6,
and obtained heterozygotes were intercrossed to generate homozygotes.
Tail or ear DNA was isolated using a DNeasy kit (Qiagen), and genotype
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analysis was performed by PCR ampliﬁcation using the following pri-
mers: 59Dlk1_F, CCAAATTGTCTATAGTCTCCCTC; 59Dlk1_R, CTGTATGAA-
GAGGACCAAGG; 59Neo_F, TTGAACAAGATGGATTGCACGCAGG; 59Neo_R,
GGCTGGCGCGAGCCCCTGATGCTCT, and a Taq DNA polymerase (Invi-
trogen). Animals were housed in plastic cages with a 12-/12-h light/dark cycle,
and fed ad libitum with normal chow (10% fat, 20% protein, 70% carbohydrate).
Speciﬁc characteristics of the animals have been described previously (21) and
are in agreement with others (19). For all animal experiments we used age- and
sex-matched animals as indicated, and all procedures were approved by the
Danish Council for Supervision with Experimental Animals (no. 2011/561–1966).
In vitro cell culture. The preadipocyte cell line 3T3-L1 was kept as previously
described (22). Brieﬂy, cells were plated at 600 cells/cm2 3 days before small
interfering RNA (siRNA) transfection at day 3 with media replaced every 24 h.
Cell culture medium consisted of Dulbecco’s modiﬁed Eagle’s medium (Lonza)
supplemented with 10% calf serum (CS; Sigma-Aldrich) and 1% penicillin-
streptomycin (PS; Lonza).
Cell number and size. Cultured cells were detached gently with 0.25% trypsin-
ethylenediaminetetraacetic acid (Gibco, Invitrogen), pelleted and resuspended
in Hanks’ balanced salt solution (HBSS, Lonza)/10% CS/1% PS. Cell number
and cell diameter were determined using a Beckman Coulter Counter Z2
(Ramcon) ﬁtted with a 100 mm aperture. The size range of particles
counted was set at 11–27 mm, and counting was performed in the indicated
number of independent experiments, each comprising triplicate measure-
ments.
Flow cytometry to determine DLK1M. Cells were detached, washed twice in
HBSS/10% CS/1% PS, and ﬁxed for 30 min on ice in 1% normal buffered form-
aldehyde. Fixed cells were washed three times and stored at 4°C in HBSS/5% CS/
1% PS/0.05% NaN3 until analysis. Cells were immunostained with rabbit a-mouse
DLK1 antibody (0.45 mg/mL) generated in house (23,24) or with rabbit immu-
noglobulin (Ig) G (control; Santa Cruz Biotechnology) for 30 min on ice. After
washing twice, samples were incubated with Alexa 488-conjugated donkey
a-rabbit IgG (1:200; Molecular Probes, Invitrogen) for 30 min on ice followed by
two washes before ﬂow cytometric analysis using a BD FACSCalibur In-
strument. The BD FACSDiva software (version 5.0.1; BD Biosciences, San Jose,
CA) was used to analyze ﬂow cytometric results. Debris was excluded from the
analysis by gating in the forward and side scatter as previously described (25–
27). The relative DLK1M levels were calculated as fold geometric Alexa-488
ﬂuorescence (sample/control) of all live cells on a given day. In parallel, the
FIG. 1. Cell cycle gene pathways are upregulated by knockdown of noncleavable Dlk1, but not cleavable Dlk1. A (top panel): The siRNA design.
Three distinct siRNAs were designed to knock down all DLK1 isoforms independently (Dlk1Total, black boxes), only cleavable DLK1 (Dlk1PS, gray
boxes), or none (scramble control), resulting in differential levels of DLK1 isoforms in 3T3-L1 preadipocytes, as indicated in the bottom panel of
A, where the ideal scenario with 100% DLK1 knockdown is depicted. As such, DLK1M represents all membrane-bound DLK1, including those Dlk1
variants that contain the protease site but that still remain on the membrane and therefore are detected by ﬂow cytometry. By contrast, DLK1S
exclusively designates Dlk1 variants containing the protease site but that have been cleaved off the membrane and thus can be measured in the
medium by ELISA. B–E: 3T3-L1 preadipocytes were transfected with either Dlk1Total, Dlk1PS, or scramble siRNA, and knockdown was veriﬁed by
qRT-PCR (B, C), ﬂow cytometry (D), and ELISA (E) at different time points after transfection. Note that DLK1S remains at the membrane until
cleavage and, logically, Dlk1PS siRNA therefore also reduces DLK1
M by 40–50% (D). Statistical signiﬁcance was tested using a one-way ANOVA
followed by a Bonferroni multiple comparisons test within each time point against scramble control. All tests resulted in P < 0.0001. F and G: 3T3-
L1 preadipocytes transfected with Dlk1Total, Dlk1PS, or scramble siRNA were examined by global gene expression arrays (n = 4). Data were log2
transformed and analyzed by the Student t test, and the number of signiﬁcantly regulated genes was examined by correcting for multiple testing
(false discovery rate). Signiﬁcantly (z > 0; P < 0.05, Westfall-Young adjustment for multiple testing) upregulated (magenta) and downregulated
(green) gene pathways were determined using GenMAPP software. Numbers of genes regulated in cell cycle related pathways are listed in
brackets. FDR, false discovery rate; TGFb, transforming growth factor b; ER, endoplasmic reticulum.
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percentage of DLK1M–positive cells in this live cell gate was measured by gating
using the control.
ELISA to determine DLK1S. Quantiﬁcation of soluble mouse DLK1S in the
culture medium of Dlk1- and scramble siRNA transfected cells was performed by
enzyme-linked immunosorbant assay (ELISA), as previously described (24). The
amount (ng/mL) of soluble DLK1 per 105 cells was calculated using cell numbers
as quantiﬁed by Coulter counting.
MTT proliferation assay. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) reduction was evaluated 48 h after Dlk1Total
2,
Dlk1PS
2, and scramble siRNA transfection. Growth medium was replaced with
Dulbecco’s modiﬁed Eagle’s medium (without phenol red) supplemented with
10% CS, 2 mM L-glutamine, and 1 mM/L pyruvate 24 h before addition of MTT
to a ﬁnal concentration of 0.5 mg/mL. After 4 h of incubation, reduced MTT
formazan crystals were solubilized overnight in a 5% sodium dodecyl sulfate/
0.005 mol/L hydrogen chloride solution, and absorbance was red at 570–690 nm.
Relative quantitative real-time PCR. Total RNA was extracted from cell
cultures or gonadal fat tissue using the semiautomated 6100 Nucleic Acid Prep
Station system according to the manufacturer’s instructions (Applied Bio-
systems). For cDNA synthesis, 0.3–0.4 mg of total RNA was reverse tran-
scribed with a High Capacity cDNA RT kit (no. 4368813; Applied Biosystems),
and quantitative real-time PCR (qRT-PCR) reactions were performed in tech-
nical triplicates with 1.5–2 ng of cDNA and 3 pM of forward and reverse primer
in a 10 mL reaction mixture using Power SYBRGreen RCR mastermix (no.
4367659; Applied Biosystems). The PCR was run on a 7900HT Fast Real-time
PCR system (Applied Biosystems) using 95°C for 10 min and the following
PCR cycling (340) conditions: denaturation at 94°C for 15 s; annealing at 57°C
for 30 s; and elongation at 72°C for 30 s. As recommended by others, robust
and valid qRT-PCR data were obtained by normalizing the raw data against
multiple stably expressed endogenous control genes as determined by the
qBase Plus platform (Biogazelle) (28,29).
siRNA-mediated knockdown. Two speciﬁc siRNAs were designed (Fig. 1A)
to differentially target either all Dlk1 mRNA splice variants (Dlk1Total:
AGAUCGUAGCCGCAACCAATT; UUGGUUGCGGCUACGAUCUCA; Ambion
no. 4390771) or only Dlk1 mRNA splice variants containing coding sequences
for the protease site for extracellular cleavage (Dlk1PS: UCCUGAAGGU-
GUCCAUGAATT; UUCAUGGACACCUUCAGGATG; Ambion no. 4399665).
Silencer Select Negative control (no. 4390846; Ambion) was used as control,
and transfections were performed for 4 h using Lipofectamine 2000 (Invi-
trogen) as previously described (22). To achieve the highest possible Dlk1
knockdown and avoid off-target effects due to high concentrations of double-
stranded RNA in the cells (30,31), we tested three slightly different siRNAs at
1–30 mM for each knockdown design as well as varying cell plating densities
(data not shown), and thereby established robust and reproducible Dlk1
knockdown conditions.
mRNA microarray expression proﬁles. RNA was reverse transcribed using
the MessageAmp II Enhanced kit (Applied Biosystems) and hybridized to
Affymetrix GeneChips (Mouse Genome 430 2.0 Array) that were run using the
GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). Data analysis was
performed using the R software (Bioconductor); expression indexes were
calculated using RMA and data were normalized using the quantile method.
Differentially expressed genes were analyzed by the Student t test with false
discovery rates to adjust for multiple tests. Gene signaling pathway analysis
was performed by the GenMAPP/MAPPFinder 2.0 software (www.genmapp
.org; Gladstone Institute, University of California San Francisco) (32,33).
Search criterions were set at a log twofold change higher than 1.1 or lower
than 0.9 and a signiﬁcance ﬁlter of unadjusted P values less than 0.05. Genes
meeting those criteria were assigned to the local MappFinder pathways and
gene families (Mapps) as well as to the gene sets of the Gene Ontology
database (Gene Ontology terms). Mapps or Gene Ontology terms were con-
sidered signiﬁcantly enriched when the z scores were above zero and the
adjusted P values were less than 0.05 (Westfall-Young adjustment for multiple
testing). Gene sets that comprised fewer than 5 or more than 100 genes
changed were excluded from the analysis because they were considered either
too speciﬁc or too general, respectively.
In vitro and in vivo 5-ethynyl-29-deoxyuridine incorporation and detec-
tion. For in vitro S-phase detection and quantiﬁcation, 5-ethynyl-29-deoxyuridine
(EdU) was added to Dlk1Total
2, Dlk1PS
2, and scramble siRNA transfected cells
to a ﬁnal concentration of 10 mM and incubated for 1 h before detachment and
ethanol ﬁxation. For each siRNA treatment, cells without EdU added were
included as negative controls. The Click-iT EdU Alexa Fluor 647 Cell Pro-
liferation Assay (Molecular Probes, Invitrogen) was used for detection of EdU
incorporation according to the manufacturer’s instructions. Samples were
analyzed using a BD LSR II Flow cytometer (BD Biosciences) with acquisition
of 10,000 cells in a live mononuclear gate. Debris was excluded by gating in
the forward and side scatter as previously described (26). Cell doublet dis-
crimination was performed by gating the single-cell population in a width
versus area plot of the propidium iodide signal (34,35).
For in vivo determination of proliferation rate, EdU was injected in-
traperitoneally to Dlk12/2 and Dlk1+/+ female mice (n = 6) at a concentration
of 50 mg EdU/g body weight. One week after injection, the stromal vascular
fraction (SVF) was isolated from the gonadal fat pads as previously described
(36) and was used for EdU analysis. Brieﬂy, gonadal fat pads were excised
from mice, weighed, washed in HBSS/100 IU/mL 1% PS, and minced exten-
sively. Tissue was digested with 0.35% type II collagenase (Worthington, U.K.)
at 37°C for 60 min, and cells were released by gentle trituration in 37°C growth
medium. A single cell suspension was obtained by ﬁltering the cell samples
through 100-mm cell strainers. Erythrocytes were lysed and isolated cells were
ﬁxed in 2% paraformaldehyde followed by permeabilization using a saponin-
based buffer as described by the manufacturer. Animals injected with PBS
were included as EdU-negative controls. EdU detection was performed as
described earlier, and SVF cells were co-stained with Rat-a-mouse-CD45 (BD
Pharmingen; 1:100) to distinguish preadipocytes present in the non-
hematopoietic (CD45-negative) fraction of the SVF. Samples were analyzed
using a BD LSR II ﬂow cytometer (BD Biosciences) with acquisition of 10,000
cells in a live mononuclear gate. Flow data were analyzed by FACSDiva
Software (version 5.0.1, BD Biosciences) with debris and cell doublets being
excluded from the analysis by gating in the forward and side scatter, as pre-
viously described (26).
Statistical analysis. For cell culture, independent experiments (n) represent
cells with at least two intervening passages. All analyses comprised 4–8 in-
dependent experiments, and one- or two-way ANOVA and two-tailed t tests were
performed as indicated (GraphPad Prism software, 5.0a Mac version) to test
signiﬁcance (P , 0.05). For animal experiments, 5–12 animals were used within
each group.
RESULTS
Cell cycle signaling pathways are differentially re-
gulated by DLK1 isoforms in preadipocytes. DLK1
exists in four major isoforms in the mouse (9) (Fig. 1A),
whereas only one cleavable and one noncleavable isoform
is present in humans (37). We designed two different siRNAs,
one speciﬁcally targeting the protease encoding site, only
present in mRNA encoding for DLK1 forms (siRNA Dlk1PS)
that may be cleaved, and another targeting an mRNA
sequence common to all Dlk1 mRNA variants (siRNA
Dlk1Total) (Fig. 1A). To our knowledge, this is the ﬁrst
study examining the function of DLK1 isoforms by spe-
ciﬁcally reducing the endogenous level of speciﬁc DLK1
variants in cells that naturally express the protein.
When we knocked down the DLK1 isoforms in proliferating
preadipocytes, we achieved 85 and 80% reductions of Dlk1Total
and Dlk1PS mRNA levels, respectively, compared with
scramble transfected cells. This highly efﬁcient knockdown
was maintained for at least 96 h (Fig. 1B and C) and suc-
cessfully conﬁrmed at the protein level (Fig. 1D and E).
To identify pathways that were differentially regulated
by cleavable and noncleavable DLK1 variants in prolifer-
ating preadipocytes, we next performed global gene ex-
pression proﬁling and found a large number of signiﬁcantly
(false discovery rate, ,0.05) regulated genes among the
three groups (Fig. 1F). Interestingly, the highest number of
signiﬁcantly regulated genes (1,156 up- and 641 downre-
gulated) was obtained by comparing the Dlk1Total- and
Dlk1PS siRNA-treated cell populations with each other
(Fig. 1F), indicating that cleavable and noncleavable DLK1
isoforms act differently, as previously suggested (7,38). Gene
signaling pathway analysis revealed that 4 of the 12 signiﬁ-
cantly regulated pathways between Dlk1Total and Dlk1PS
siRNA-transfected cells (Fig. 1G) concerned cell cycle con-
trol, especially in relation to the G1- to S-phases (Fig. 2A).
Relative qRT-PCR supported our microarray data and
showed that genes known to promote cell cycle progression
(Ccnd1, Ccnd3, Ccne2, Cdk6, Cdc25a, and Mcm5–7) were
all signiﬁcantly upregulated ;27–94% (P , 0.001–0.01) in
Dlk1Total knockdown cells, whereas all these genes except
Cdkn1awere unaffected or even signiﬁcantly downregulated
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FIG. 2. Noncleavable Dlk1 regulates numerous genes during the G1-to-S-phase transition. A: Relative variation of gene expression in Dlk1Total
versus Dlk1PS siRNA transfected 3T3-L1 preadipocytes at 48 h, as determined using GenMAPP software. Upregulated genes are magenta (P< 0.05)
and purple (0.05 < P < 0.2), and downregulated genes are dark green (P < 0.05) and green (0.05 < P < 0.2). P values have been assigned to each
gene after log2 transformation and a Student t test. B: Relative qRT-PCR of cell cycle–associated genes at 24–96 h after transfection of 3T3-L1
preadipocytes with DLK1Total, DLK1PS, or scramble siRNA. Signiﬁcance was tested by a one-way ANOVA followed by a Bonferroni multiple com-
parisons test within each time point against scramble control. *P < 0.05; **P < 0.01; ***P < 0.0001. Raw data were normalized against multiple
stably expressed reference genes (data not shown).
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in Dlk1PS siRNA-transfected cells (Fig. 2B). Cdkn1a is
known to be decreased in DLK1 over-expressing liver cells
(39), which is in agreement with our results.
Thus, simultaneous knockdown of cleavable and non-
cleavable DLK1 variants, but not cleavable DLK1 alone,
results in enhanced expression of genes that are known to
promote cell cycle progression, suggesting that only
DLK1M affects preadipocyte proliferation. However, it is
also possible that cleavable and noncleavable DLK1 var-
iants exert similar effects and that the amounts of non-
cleavable DLK1 remaining on the membrane when only
cleavable DLK1 forms are knocked down are sufﬁcient to
prevent an increase in proliferation-associated events. To
test for this possibility, we restored the level of soluble
DLK1S in Dlk1Total knocked down cells by adding different
amounts of conditioned preadipocyte medium containing
soluble DLK1 or puriﬁed human soluble DLK1 to the cul-
ture medium and examined the effect on cyclin expression
levels. However, no apparent difference in the levels of
Ccnd1, Ccnd3, and Ccne2 were found (Fig. 3), suggesting
that only noncleavable DLK1 isoforms exert an inhibitory
function on preadipocyte proliferation.
Membrane-tethered DLK1 inhibits preadipocyte pro-
liferation in vitro by lowering the number of cells in
the S phase of the cell cycle. We next performed an
EdU cell cycle distribution assay, which is a new and far
more robust method to detect S-phase cells than con-
ventional 5-bromo-2-deoxyuridine (BrdU) assays (40). As
expected, we found that 40.1 6 1.6% (P = 0.0006) and
34.0 6 1.4% (P = 0.02) of Dlk1Total
2 and Dlk1PS siRNA-
treated cells were present in the S phase at 48 h, whereas
only 30.7 6 1.6% of scramble control cells were repli-
cating (Fig. 4A and B).
We next determined the proliferative capacity of
Dlk1Total, Dlk1PS, and scramble siRNA-transfected cells.
Cell numbers were signiﬁcantly elevated (38%; P , 0.001,
one-sample t test) in Dlk1Total transfected cells compared
with scramble control cells (Fig. 4C). This effect was much
less pronounced but still signiﬁcant (14%; P , 0.05, one-
sample t test) in Dlk1PS knocked down cells (Fig. 4C).
Previous studies have suggested that the cleavable form of
DLK1 has a hypotrophic effect on adipocytes (19,20). In
agreement, we found a small but signiﬁcant increase in cell
size (1.8%; P , 0.001) in only Dlk1PS siRNA-transfected
cells (Fig. 4D). However, this minor effect may be in-
signiﬁcant in a physiological sense. Nevertheless, the en-
hanced proliferation was conﬁrmed by higher MTT levels
(Fig. 4E) and an increased expression of the proliferation
marker Ki-67 (43%; P , 0.001) (Fig. 4F). Finally, we re-
stored the level of cleaved DLK1 in Dlk1Total knocked
down cells and found that cleaved DLK1 alone did not
reduce cell numbers (Fig. 4G and H), which is in agree-
ment with the lack of a suppressive effect on cyclin gene
expression, as described earlier (Fig. 3).
Adipose tissue expansion in Dlk12/2 mice due to in-
creased preadipocyte proliferation. It has been sug-
gested that the Dlk1 knockout mouse possesses increased
amounts of adipose tissue (19,21) as a sole consequence of
DLK1 inhibiting adipocyte hypertrophy (19,20), which pre-
viously was the general view of how fat expansion oc-
curred. Recently, it has become clearer that adipocyte
numbers also determine fat content (1–3), and we therefore
FIG. 3. Restoration of cleaved DLK1 levels in the medium of Dlk1Total knocked down 3T3-L1 cells. 3T3-L1 cells were transfected at 0 h with either
Dlk1Total or scramble siRNA and grown in either 3T3-L1–conditioned medium (Cond. med.) (A) or a medium containing known concentrations of
puriﬁed human DLK1 (hDLK1) (B). mRNA levels of cell cycle–related genes were determined by qRT-PCR 48 h after transfection. Signiﬁcance was
tested by a two-way ANOVA (**P < 0.01; ***P < 0.0001), and qRT-PCR raw data were normalized against multiple stably expressed endogenous
controls (data not shown).
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hypothesized that obesity in the Dlk1 knockout mouse also
could be explained by an increased proliferation of pre-
adipocytes residing in vivo, as our in vitro results suggest.
Thus, to support our in vitro data, we performed qRT-PCR
on gonadal adipose tissue from Dlk12/2 and Dlk1+/+ mice
and found substantially increased (26–67%; P , 0.05–0.001)
levels of cell cycle–promoting genes (Ccnd1, Ccne2, and
Ccnd3, Mcm5–6) (Fig. 5A). No difference was observed
between sexes (data not shown), which is in agreement with
a previous study (19) showing that both female and male Dlk1
knockouts possess higher amounts of fat compared with their
respective wild-type littermates. No Dlk1 expression was
present in adipose tissue from the Dlk12/2 mice (Fig. 5A),
conﬁrming the lack of Dlk1 in the knockout mice (21).
FIG. 4. Membrane-bound DLK1 restricts in vitro preadipocyte proliferation by repressing G1-to-S-phase transition. A, B: The number of 3T3-L1
preadipocytes in the S phase of the cell cycle was quantiﬁed by EdU incorporation 48 h after transfection with Dlk1Total, Dlk1PS, or scramble siRNA.
Cell doublets and debris were excluded from the ﬂow cytometric analysis, and EdU+ gating was established within each siRNA treatment from
negative controls that did not receive any EdU. C–F: Proliferation capacity was examined in Dlk1Total, Dlk1PS, or scramble siRNA-treated cells
using Coulter counting (C, D), MTT (E), and qRT-PCR (F). G, H: Dlk1Total and scramble siRNA-transfected 3T3-L1 preadipocytes were cultured in
the presence of different percentages of (G) conditioned medium (Cond. med.) from proliferating 3T3-L1 preadipocytes or (H) puriﬁed human
DLK1 (ng/mL). Cell numbers were then examined by Coulter counting at 72 h. Signiﬁcance was tested by Student t test (A–E), a one-way ANOVA
followed by a Bonferroni multiple comparisons test within each time point against scramble control (F), and two-way ANOVA (*P < 0.05; **P <
0.01; ***P < 0.0001) (G, H). qRT-PCR raw data in (F) were normalized against multiple stably expressed reference genes (data not shown).
S.B. MORTENSEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, NOVEMBER 2012 2819
To test our novel results on a functional level in vivo, we
next quantiﬁed the proliferative capacity of preadipocytes
in young mice, when the gonadal adipose tissue is sup-
posed to be established (1,3). In general, there is a major
lack of knowledge about the phenotype and identity of
preadipocytes in vivo (4). Because we intended to conﬁrm
only our in vitro data and not to exclude any preadipocytes
by selecting the wrong preadipocyte markers, we chose to
analyze the adipose-derived, CD45-negative portion of the
stromal vascular fraction because this is generally accepted
to comprise all preadipocytes. We therefore administered
the nucleoside analog EdU into 5-week-old Dlk12/2 and
Dlk1+/+mice and determined its incorporation into CD452SVF
cells after 1 week (Fig. 5B and E). In wild-type mice we
found that 3.7% (mean, n = 6) of the CD452SVF had been
proliferating (Fig. 5B and C), a ﬁgure highly similar to what
was reported recently for preadipocytes in 6-week-old
mice (2) and which conﬁrms our experimental setup. For
comparison, 7.0% (mean, n = 5) of the CD452SVF in the
Dlk12/2 mice were EdU positive (Fig. 5B–C), suggesting
that nearly twice as many preadipocytes are proliferating
in the absence of DLK1. By measuring the relative total
amount of incorporated EdU, we also established that
Dlk12/2 preadipocytes contained 38% more EdU than their
wild-type littermates (Fig. 5D), indicating that the Dlk12/2
preadipocytes not only are higher in numbers, but they
FIG. 5. DLK1 represses cell cycle gene expression and proliferation of preadipocytes in vivo. A: Expression analysis by qRT-PCR of several cell
cycle genes in gonadal fat tissue from Dlk1+/+ or Dlk12/2 mice (n = 12; 6 males and 6 females within each group). B–E: Flow cytometric analysis of
EdU/CD45 in SVF cells isolated from gonadal fat tissue of Dlk1+/+ or Dlk12/2 mice injected with 50 mg/mL/kg of EdU 1 week before SVF isolation
and analysis. The number of SVF cells isolated per milligram of fat was counted by Coulter counting. F: The DNA content per milligram of gonadal
fat tissue in Dlk1+/+ and Dlk12/2 mice. Signiﬁcance was tested by a Student t test (*P < 0.05; **P < 0.01), and qRT-PCR raw data in (A) were
normalized against multiple stably expressed reference genes (data not shown).
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also have progressed through the cell cycle more times
than Dlk1+/+ preadipocytes. Overall, we found that Dlk12/2
mice possessed 3.5 times more proliferating preadipocytes
per milligram of fat than their wild-type littermates (Fig.
5E), which was conﬁrmed by a tendency of Dlk12/2 fat to
contain more DNA per milligram of fat than Dlk12/2 mice
(Fig. 5F). Thus, our in vivo results conﬁrm our in vitro data
that Dlk1 inhibits preadipocyte proliferation.
DISCUSSION
Adipose tissue expansion is known to occur through pro-
liferation and differentiation of preadipocytes; however,
the mechanisms especially responsible for preadipocyte
proliferation are incompletely understood (4). Numerous
data suggest that only cleaved DLK1 inhibits adipogenesis
by interfering with the differentiation machinery (8), but
our results invoke an additional explanation suggesting
that DLK1M slows preadipocyte proliferation by regulating
numerous components in the G1-S phase of the cell cycle.
As such, we have examined the effect on preadipocyte
proliferation of cleavable and noncleavable DLK1 isoforms
by speciﬁcally reducing the endogenous level of speciﬁc
DLK1 variants in cells that naturally express the protein.
Although one study previously used antisense RNA mole-
cules to study DLK1’s function in adipocyte differentiation
(7), the role of DLK1 has only been assessed by over-
expressing the protein in cell types lacking endogenous Dlk1
(13,41) or expressing different endogenous DLK1 levels
(10,39,42). Consequently, these previous studies have in-
troduced a concentration variable that has been suggested to
be an important factor for DLK1’s function (14). We believe,
therefore, that this study provides a novel setup that mimics
biology more closely than those used in the previous studies
described earlier. Furthermore, this study is one of a few
(13,15) that have focused on investigating whether different
functions exist for DLK1M and soluble DLK1. In this study,
we used mRNA arrays and identiﬁed four cell cycle–related
signaling pathways that were regulated differentially by
cleavable and noncleavable DLK1 isoforms. However, many
of the genes only differed by 20–50% in the qRT-PCR veriﬁ-
cation. Such a small statistically signiﬁcant change may not
be biologically relevant per se, but in our case we chose the
genes to be validated at random and therefore cannot rule
out that other cell cycle genes may have differed more.
Furthermore, we clearly showed that many components, and
not merely a few genes, in the cell cycle all are affected at
different time points in the same direction of having more
proliferation in the treated cells. Most importantly, however,
we saw a substantial functional change in the proliferation
rate of the treated cells, and we therefore believe that our
results are very strong indeed. Accordingly, we found a 0, 14,
and 38% increase in the proliferative rate of scramble, Dlk1PS
and Dlk1Total siRNA-treated preadipocytes, respectively, and,
bearing in mind that these cells exhibit 100, 45, and 15%
membrane DLK1, it seems highly likely that the lower levels
of DLK1M increase preadipocyte proliferation. This is in
agreement with another study, which showed that ectopic
expression of only full-length membrane spanning, and not
soluble DLK1, diminishes proliferation of leukemic cells with
a slower progression through the transition from the G1 to
the S phase (41). However, this phenomenon may be cell
type/tissue speciﬁc because DLK1 over-expression in some
cancer cell lines with a small but signiﬁcant level of endog-
enous DLK1 reveals that both cleavable and noncleavable
DLK1 isoforms promote S-phase cell cycle progression
(39,42). Our results showing that cleavable DLK1 does not
exert an effect on preadipocyte proliferation is in line with
a previous study showing that DLK1 mutants encoding only
the cleavable DLK1 isoform do not have an impact on he-
matopoietic cell proliferation (41). By contrast, Bray et al.
(13) showed that Drosophila mutants expressing either
cleavable or noncleavable DLK1 result in fewer and higher
cell numbers, respectively, indicating that both DLK1 iso-
forms in some way may be important for cell proliferation
and likely have opposite or interfering actions. We also can-
not rule out that much higher nonphysiological concen-
trations of cleaved DLK1 may have a suppressive effect on
cell proliferation or, as recently reported (43), that DLK1
isoforms exert their effects with different potencies, with the
DLK1M being far more effective. However, our in vivo results
clearly support our in vitro data, ﬁrmly demonstrating that
DLK1 in vivo inhibits preadipocyte proliferation and not only
induces adipocyte hypertrophy, as previously assumed
(19,20). Yet it should be noted that our in vivo data do not
allow us to distinguish between the cleavable and non-
cleavable DLK1 isoforms. Nevertheless, the data presented
here together ﬁrmly establish that DLK1 inhibits preadipocyte
proliferation in its membrane-bound but not soluble form,
which instead exerts its inhibitory adipogenic effect on adi-
pocyte differentiation, as shown by others (7,10,18–20,44).
Conclusively, we believe that this novel and dual func-
tion of DLK1 ﬁrmly places this molecule as a major regu-
lator of adipogenesis, and further insights into DLK1
signaling will be important and may serve to unravel novel
candidate targets to treat obesity.
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